EGFR and colorectal carcinoma: These results show that by depleting EGFR and HER2 in CRC cells, PEPDG278D not only directly suppresses both RTKs but also indirectly suppresses other RTKs by disrupting their association with EGFR or HER2, thereby causing extensive inhibition of oncogenic signaling.